a 92

GCN2-IN-1 (A-92) is an effective GCN2 inhibitor and can be utilized in cancer research as a chemotherapeutic agent.

Peptide derived from the tumor suppressor protein p16; inhibits cyclin-dependent kinase-4 (cdk4)/cyclin D1 (IC50 ~ 1.5 μM) and binds to cdk6.

NNC 92-1687 is a selective glucagon receptor antagonist that can be used to study type 2 diabetes.

(5R)-BW-4030W92, the active enantiomer of BW-4030W92, is an orally available, non-selective, voltage-dependent, and use-dependent sodium channel antagonist used in the study of neurological disorders.

gamma-preprotachykinin amide (72-92) acetate is a 21 amino acid peptide belonging to the tachykinin (TK) family and including neurokinin A (NKA) in its C-terminal sequence. gamma-preprotachykinin amide (72-92) acetate possesses higher affinity than NKA for central NK-2 receptors; it shows lower affinity for NK-1 receptors, however, it potently stimulates salivary secretion, which is mediated by NK-1 receptor activation.

MRT-92 is an antagonist of Smoothened (Smo) with anti-cancer activity, featuring a binding affinity (Ki) of 0.7 nM. It inhibits the Hedgehog signaling pathway by obstructing the overlapping binding sites within the transmembrane domain of the Smoothened receptor and suppresses the proliferation of cerebellar granule cells in rodents (IC50=0.4 nM). MRT-92 is utilized for research into cerebellar gliomas.

E3LigaseLigand-linker Conjugate 92 is a conjugate of an E3 ligase ligand and a linker (E3LigaseLigand-Linker Conjugates), composed of Thalidomide and the corresponding linker. E3LigaseLigand-linker Conjugate 92 functions as a Cereblon ligand to recruit the CRBN protein and serves as a crucial intermediate in the synthesis of complete PROTAC molecules.

α-Glucosidase-IN-92 (compound 14b) is a non-competitive inhibitor targeting α-glucosidase with an IC50 of 64.0 μM, displaying greater inhibitory potency than Acarbose (IC50=750 μM). It has excellent oral bioavailability and can cross the blood-brain barrier. This compound slows carbohydrate hydrolysis and reduces postprandial blood glucose levels, making it useful for antidiabetic studies in type 2 diabetes.

AChE-IN-92 (Compound L4R1-3) is a highly selective acetylcholinesterase (AChE) inhibitor with an IC50 of 4.6 nM. It effectively prevents the hydrolysis of acetylcholine, thereby increasing its levels in the synaptic cleft. AChE-IN-92 holds potential for research in Alzheimer's disease (AD).

KN-92 phosphate (KN92-H3PO4) is an inactive derivative of KN-93. KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII), competitively blocking CaM binding to the kinase (Ki = 370 nM).

MRT-92 is a potent and selective Smoothened (Smo) receptor inhibitor. MRT-92 displays subnanomolar antagonist activity against Smo in various Hh cell-based assays. MRT-92 inhibits rodent cerebellar granule cell proliferation induced by Hh pathway activation through pharmacologic (half maximal inhibitory concentration [IC50] = 0.4 nM) or genetic manipulation. Smo is the target of anticancer drugs that bind to a long and narrow cavity in the 7-transmembrane (7TM) domain.

CD4 (81-92) is a peptide that was previously found to inhibit gp120 binding, HIV-1 infectivity, and syncytium formation.

Antibacterial agent 92, a triple-site aminoacyl-tRNA synthetase (aaRS) inhibitor, demonstrates a potent antibacterial effect by inhibiting Salmonella enterica threonyl-tRNA synthetase (SeThrRS) with an IC50 of 0.58 μM.

Prepro-ANF (56-92), human, a precursor to the human atrial natriuretic factor, activates guanylate cyclase by specifically enhancing particulate guanylate cyclase activity within the renal membrane and unit [1].

Leucettinib-92 is a small-molecule inhibitor of the DYRK and CLK kinase families that exhibits differential inhibitory activity across multiple kinases, with IC50 values of 147 nM for CLK1, 39 nM for CLK2, 5.2 nM for CLK4, 0.8 μM for CLK3, 124 nM for DYRK1A, 204 nM for DYRK1B, 0.16 μM for DYRK2, 1.0 μM for DYRK3, 0.52 μM for DYRK4, and 2.78 μM for GSK3, supporting its use in kinase signaling and regulatory mechanism research.

PKCε (85-92) (ψεRACK) is a peptide and selective PKCε activator that does not affect the activity of other PKC isozymes.PKCε (85-92) induces a pro-angiogenic response in endothelial cells, promotes FGF-2 cytosolization, and regulates VEGF activity.

PKC(85-92),Myristoylated is a myristic acid-conjugated, cell-permeable peptide activator of PKC that has been shown to increase nitric oxide (NO) release in cultured human umbilical vein endothelial cells (HUVECs) [1].

MOG (92–106), mouse, rat, is a biologically active peptide corresponding to the fragment of amino acids 92 to 106 in myelin oligodendrocyte glycoprotein (MOG) from mice and rats. Mice subjected to MOG (92–106)-induced experimental autoimmune encephalomyelitis show substantial B cell reactivity to secondary myelin antigens. Although this MOG fragment elicits only modest T cell responses, the resultant autoimmunity is profoundly severe. The peptide demonstrates encephalitogenic properties in various species, including SJL mice, DA rats, and rhesus monkeys.

KN-92 hydrochloride is an inactive derivative of the selective Ca2+/calmodulin-dependent kinase II (CaMKII) inhibitor KN-93, which competitively blocks CaM binding to the kinase with a Ki of 370 nM.

SRS11-92 (AA9) is a ferroptosis inhibitor and a derivative of ferrostatin-1

gamma-preprotachykinin amide (72-92) is a useful organic compound for research related to life sciences. The catalog number is T9417 and the CAS number is 114882-65-4.

Proadrenomedullin (45-92), human, a mid-regional fragment of proadrenomedullin (MR-proADM), consists of amino acids 45–92 of pre-proADM.

[(Cys(Bzl)84, Glu(OBzl)85)]CD4 (81-92) is a selective HIV-1 inhibitor that blocks the interaction between HIV-1 and CD4 molecules, thereby inhibiting viral infection and cell fusion. At a concentration of 25 μM, it can completely prevent fusion formation [1].

XMD8-92 is an effective and specific BMK1/ERK5 inhibitor (Kd: 80 nM).